C
CIN Terminal
Cannabis Investor News
A CanIDeal, Inc. Company
J
Live
Loading market data...
Expand
Symbol Name Exchange Last Change Volume Watch
Home Markets Loading…
VEXTF Equity

Vext Science

OTCMKTS · VEXTF

$0.18
Live Price
Price History 5 Years

Analyst Coverage

Cannabis Investor News in-house rating · cin-analyst-v1.0

Neutral Conviction 1/5
48/100 composite
Fundamentals60
Regulatory49
Market40
Editorial30
Composite · trailing 12 months

The CIN framework assigns Vext Science a Neutral rating at 48/100, with conviction of 1 out of 5. The composite is a fixed blend of four pillars — fundamentals at 35 percent, regulatory at 25, market at 25, and editorial at 15 — and each contribution is inspectable. The strongest contribution comes from the fundamentals pillar at 60, and pulls the composite into the middle of the band. Editorial lags at 30, softening what would otherwise be a stronger reading.

Under the hood, the data points sit as follows: reported revenue growth of 5.2 percent year over year, an operating margin of 0.0 percent. Each of those figures ties back to a specific input in the pillar breakdown. Every input flowing into the pillar table comes from primary regulatory filings, licensed fundamentals data, and institutional pricing feeds, filtered through CIN newsroom density. The 336-ticker CIN universe is scored deterministically, so Vext Science can be compared against the US operator peer set on identical inputs, refreshed on the ingest cycle.

The clearest catalyst is the next quarterly print. Fundamentals contribute 60 of the composite, and either an acceleration in top-line growth or a stabilization of the operating margin would move the score higher; a deterioration on either would compress it.

Scored: 2026-07-14Valid through: 2026-08-28Weights: Fundamentals 35% · Regulatory 25% · Market 25% · Editorial 15%
Loading CIN Rating…
Fundamentals SEC & Market Data
Loading fundamentals…
Analyst Consensus
Loading analyst data…
Valuation Multiples
Loading…
Price Statistics
Loading…
Financing Activity
Loading financing data…
Insider Transactions
Loading insider data…
Regulatory Filings
Loading regulator disclosures…
Peer Comparison
Loading peer data…
Institutional DetailIR, corporate, and filing data from CIN enrichment
IR & AgencyInvestor relations
Corporate DetailsCompany profile
CEO
Eric Offenberger
CFO
Trevor Smith
SEC CIK
0001778028
Website
Company website
Fundamentals & FinancialsRefreshed nightly from licensed fundamentals data
Market cap
$40.6M
Enterprise value
$68.6M
Price to book
0.75
Price to sales
0.78
EV / EBITDA
8.36
Revenue (TTM)
$52.0M
Gross profit (TTM)
$17.7M
EBITDA
$10.0M
Operating margin
0.0%
Profit margin
-29.9%
Rev growth YoY
5.2%
Return on equity
-24.5%
Return on assets
-2.5%
EPS (TTM)
$-0.06
EPS est. current year
$-0.01
Wall St. target price
$0.60
Shares outstanding
185.8M
Insider ownership
45.7%
Institutional ownership
0.4%
Beta
0.80
GICS sector
Healthcare
GICS industry
Drug Manufacturers - Specialty & Generic
Filings & DisclosuresPrimary sources
Filing portal
SEC EDGAR
See something incorrect or missing?

Help us keep coverage accurate. Submit an update for CIN editorial review.

Submit an update
Complimentary Research
Would you like a deeper analysis on this company?

Request a complimentary, fully customized institutional-quality research report — tailored to your investment thesis.

Request Complimentary Report

Bullish and Bearish Analyst Opinions for Vext Science (VEXTF)

Cannabis Investor News aggregates analyst coverage, price targets, insider transactions, SEC filings, and financing activity for Vext Science (VEXTF), a cannabis-sector equity listed on OTCMKTS. Use this profile to compare bullish and bearish opinions, monitor Form 4 insider buys and sells, and review the latest quarterly results.

CIN editorial stance: Risk Elevated. Headwinds: deep drawdown. (0 bullish signals, 2 bearish signals.)

Bullish and bearish analyst opinions for Vext Science (VEXTF)

Bullish view. Vext Science is a tightly-run Arizona-anchored MSO with recent expansion into Ohio's adult-use market; bulls model EBITDA growth as Ohio ramps and the balance sheet stays disciplined relative to Tier-2 MSO peers.

Bearish view. Bears cite concentration in Arizona (a saturated market), the OTC listing that limits institutional participation, and the small-cap capital-access disadvantage relative to Tier-1 MSOs.

Live ratings, price targets, and consensus figures for Vext Science appear above this summary. Explore analyst coverage across the 326-equity cannabis universe.

Historical Price Data

5-year weekly price history, intraday quotes, and 52-week range for VEXTF are maintained by Cannabis Investor News and refreshed throughout the trading day.